Jazz Pharmaceuticals
$235.67Change from previous close: +1.14%Absolute change: +$2.66
At a glance
- Revenue growth
- +4.88%
- 2025 vs 2024
- Net margin
- -8.3%
- 2024: 13.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 4,268 | 4,069 | 3,834 | 3,659 | — |
| Cost of revenue | 503 | 446 | 436 | 541 | — |
| Gross profit | 3,764 | 3,623 | 3,399 | 3,119 | — |
| Selling, general and administrative | 1,809 | 1,385 | 1,343 | 1,417 | — |
| Research and development | 783 | 884 | 850 | 590 | — |
| Operating income | 518 | 727 | 598 | 512 | — |
| EBIT | -433 | 708 | 587 | -84.5 | — |
| EBITDA | 263 | 1,369 | 1,226 | 545 | — |
| Interest expense | 195 | 238 | 289 | 288 | — |
| Pre-tax income | -628 | 470 | 298 | -373 | — |
| Income tax | -272 | -91.4 | -120 | -159 | — |
| Net income | -356 | 560 | 415 | -224 | — |
| Net income to common shareholders | -356 | 560 | 415 | -224 | — |
| Basic EPS | -5.84 | 9.06 | 6.55 | -3.58 | — |
| Diluted EPS | -5.84 | 8.65 | 6.10 | -3.58 | — |
| Average shares (basic) | 61.0 | 61.8 | 63.3 | 62.5 | — |
| Average shares (diluted) | 61.0 | 66.0 | 72.1 | 62.5 | — |